New England Capital Financial Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$282K Buy
2,193
+11
+0.5% +$1.29K 0.07% 53
2026
Q1
$262K Buy
2,182
+12
+0.6% +$1.39K 0.07% 51
2025
Q4
$228K Buy
2,170
+14
+0.6% +$1.31K 0.09% 58
2025
Q3
$181K Sell
2,156
-84
-4% -$6.92K 0.08% 60
2025
Q2
$177K Buy
2,240
+14
+0.6% +$1.11K 0.08% 58
2025
Q1
$200K Sell
2,226
-179
-7% -$16.7K 0.1% 51
2024
Q4
$239K Buy
2,405
+16
+0.7% +$1.65K 0.12% 51
2024
Q3
$271K Buy
2,389
+14
+0.6% +$1.66K 0.14% 48
2024
Q2
$294K Buy
2,375
+14
+0.6% +$1.8K 0.16% 42
2024
Q1
$312K Buy
2,361
+14
+0.6% +$1.73K 0.18% 40
2023
Q4
$256K Buy
2,347
+16
+0.7% +$1.66K 0.15% 47
2023
Q3
$240K Buy
2,331
+14
+0.6% +$1.51K 0.17% 44
2023
Q2
$267K Sell
2,317
-99
-4% -$11.2K 0.18% 43
2023
Q1
$257K Sell
2,416
-188
-7% -$20.3K 0.18% 45
2022
Q4
$286K Buy
+2,604
New +$266K 0.2% 41

Other funds holding MRK

New England Capital Financial Advisors's MRK Position: Q2 2026 in Review

New England Capital Financial Advisors increased its Merck (MRK) stake by 0.5% in Q2 2026, buying an estimated $1.29K and bringing the position to 2,193 shares worth $282K. The position accounts for 0.07% of the portfolio, ranked #53.

New England Capital Financial Advisors first reported a position in MRK in Q4 2022 and has held it in 15 quarters since. The position peaked at $312K in Q1 2024. 1,865 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • New England Capital Financial Advisors held 2,193 shares of Merck worth $282K as of Q2 2026.
  • New England Capital Financial Advisors bought 11 Merck shares in Q2 2026, an estimated $1.29K.
  • Merck made up 0.07% of New England Capital Financial Advisors's portfolio in Q2 2026, its #53 holding.
  • New England Capital Financial Advisors first reported a position in Merck in Q4 2022 and has held it in 15 quarters since.
  • New England Capital Financial Advisors's Merck position peaked at $312K in Q1 2024.
  • 1,865 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on New England Capital Financial Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.